We’re the plan to change the future type. JDRF research focuses on key therapies that hold significant promise in turning Type One into Type None, including: artificial pancreas, encapsulation, smart insulin, restoration, and prevention.
Step into the shoes of someone living with type 1 diabetes (T1D) for one day in an eye-opening text campaign made possible through the generous support of Lilly Diabetes. In just a single day, you’ll gain a deeper understanding of the challenges people with T1D face. Sign up today, or any day in November, and […]
JDRF is kicking off National Diabetes Awareness Month by turning the Empire State Building blue! On the evening of November 1—T1Day—New York’s iconic landmark will blaze blue to promote diabetes awareness and show support for the 366 million people worldwide living with both type 1 diabetes (T1D) and type 2 diabetes. Awareness for T1D doesn’t […]
JDRF and Ford Customer Service Division (FCSD) joined forces to help raise awareness and funds for type 1 diabetes (T1D) research through the “Our Everyday Heroes” Race Car Design Contest for JDRF. The winning design was painted onto the Motorcraft/Quick Lane Ford Shelby Mustang Funny Car driven by Bob Tasca III. The contest has raised […]
A Letter from Jeffrey Brewer April 21-27, 2013, is National Volunteer Week, a time to celebrate and express our gratitude for all that volunteers do to make a difference in our communities. Of course at JDRF, every week is national volunteer week and, in that spirit, I thank you for all your dedication and support […]
Nicole Johnson, a member of the JDRF International Board of Directors, has been named the Tampa Bay Lightning NHL team’s 35th Lightning Community Hero for her work as a diabetes consultant and advocate. The award honors members of the Tampa Bay community for their outstanding charitable work with a $50,000 donation to the recipient’s designated […]
Cycle along with Novo Nordisk—the official national presenting sponsor of the JDRF Ride to Cure Diabetes. A global healthcare company with 90 years of innovation and leadership in diabetes care, Novo Nordisk and its staff have supported the JDRF Ride to Cure Diabetes for nearly a decade. Now, CEO Lars Rebien Sørensen and President Jerzy […]
Question: I am a parent with type 1 diabetes. My children are now ages seven and two, and they are asking questions about it. How do I explain to them what type 1 diabetes is in a way that will help them understand and not be scared? Answer: I have been in this exact same […]
JDRF would love to hear from you about our first-ever digital annual report. Please share your feedback with us!
Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).